We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for lanadelumab (Takeda Pharmaceuticals Australia Pty Ltd)
Active ingredients
lanadelumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for injection
Indication
Lanadelumab is indicated for the routine prevention of angioedema attacks and control of symptoms of HAE in paediatric patients 2 to <12 years
Therapeutic area
Immunology